Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms
Background: Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Series: | Phytomedicine Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667031321000397 |
| _version_ | 1818461942777380864 |
|---|---|
| author | Sophie Chabot Nishtman Dizeyi Lena Ramnemark Philippe Lluel Per-Anders Abrahamsson Magnus Grabe |
| author_facet | Sophie Chabot Nishtman Dizeyi Lena Ramnemark Philippe Lluel Per-Anders Abrahamsson Magnus Grabe |
| author_sort | Sophie Chabot |
| collection | DOAJ |
| description | Background: Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a regulatory effect on inflammatory parameters. Methods: In this study, male Sprague Dawley rats were used to validate the effects of Cernitin™ in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. Results: Cernitin™ exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue homogenates. In a parallel study, Cernitin™ treatment led to a significant decrease in prostate weight in rats with testosterone induced BPH. Concurrently, a significant decrease in the percentage of proliferation marker, Ki-67, and androgen receptor expressing cells was observed. Similarly, a low level of cytoplasmic 5α-reductase expression was observed in Cernitin™- and finasteride-treated animals. Conclusion: The current in vivo experiments support the use of Cernitin™ as an anti-inflammatory and symptom reducing agent that could, in part, explain the impact of Cernitin™ on the management of chronic pelvic pain in men. |
| first_indexed | 2024-12-14T23:54:10Z |
| format | Article |
| id | doaj.art-e777f6ffc0a24726a1962ea4871ce9be |
| institution | Directory Open Access Journal |
| issn | 2667-0313 |
| language | English |
| last_indexed | 2024-12-14T23:54:10Z |
| publishDate | 2021-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Phytomedicine Plus |
| spelling | doaj.art-e777f6ffc0a24726a1962ea4871ce9be2022-12-21T22:43:10ZengElsevierPhytomedicine Plus2667-03132021-11-0114100057Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptomsSophie Chabot0Nishtman Dizeyi1Lena Ramnemark2Philippe Lluel3Per-Anders Abrahamsson4Magnus Grabe5Urosphere, Toulouse, FranceAB Cernelle, Ängelholm, Sweden; Department of Translational Medicine, Urologic Research, Lund University, Malmö, Sweden; Corresponding author at: Department of Translational Medicine, Urologic Research, Lund University, Malmö, Sweden.AB Cernelle, Ängelholm, SwedenUrosphere, Toulouse, FranceAB Cernelle, Ängelholm, Sweden; Department of Translational Medicine, Urologic Research, Lund University, Malmö, SwedenDepartment of Translational Medicine, Urologic Research, Lund University, Malmö, SwedenBackground: Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a regulatory effect on inflammatory parameters. Methods: In this study, male Sprague Dawley rats were used to validate the effects of Cernitin™ in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. Results: Cernitin™ exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue homogenates. In a parallel study, Cernitin™ treatment led to a significant decrease in prostate weight in rats with testosterone induced BPH. Concurrently, a significant decrease in the percentage of proliferation marker, Ki-67, and androgen receptor expressing cells was observed. Similarly, a low level of cytoplasmic 5α-reductase expression was observed in Cernitin™- and finasteride-treated animals. Conclusion: The current in vivo experiments support the use of Cernitin™ as an anti-inflammatory and symptom reducing agent that could, in part, explain the impact of Cernitin™ on the management of chronic pelvic pain in men.http://www.sciencedirect.com/science/article/pii/S2667031321000397Cernitin™Cernilton®ProstatitisCytokinesBenign prostatic hyperplasia |
| spellingShingle | Sophie Chabot Nishtman Dizeyi Lena Ramnemark Philippe Lluel Per-Anders Abrahamsson Magnus Grabe Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms Phytomedicine Plus Cernitin™ Cernilton® Prostatitis Cytokines Benign prostatic hyperplasia |
| title | Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms |
| title_full | Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms |
| title_fullStr | Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms |
| title_full_unstemmed | Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms |
| title_short | Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms |
| title_sort | impact of cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms |
| topic | Cernitin™ Cernilton® Prostatitis Cytokines Benign prostatic hyperplasia |
| url | http://www.sciencedirect.com/science/article/pii/S2667031321000397 |
| work_keys_str_mv | AT sophiechabot impactofcernitinoninducedchronicprostatitisinanimalmodelforunderstandingmanagementoflowerurinarytractsymptoms AT nishtmandizeyi impactofcernitinoninducedchronicprostatitisinanimalmodelforunderstandingmanagementoflowerurinarytractsymptoms AT lenaramnemark impactofcernitinoninducedchronicprostatitisinanimalmodelforunderstandingmanagementoflowerurinarytractsymptoms AT philippelluel impactofcernitinoninducedchronicprostatitisinanimalmodelforunderstandingmanagementoflowerurinarytractsymptoms AT perandersabrahamsson impactofcernitinoninducedchronicprostatitisinanimalmodelforunderstandingmanagementoflowerurinarytractsymptoms AT magnusgrabe impactofcernitinoninducedchronicprostatitisinanimalmodelforunderstandingmanagementoflowerurinarytractsymptoms |